A Phase I/IIa Open-label Investigation of the Safety and Effectiveness of DIABECELL [Immunoprotected (Alginate-Encapsulated) Porcine Islets for Xenotransplantation] in Patients With Type I Diabetes Mellitus

Trial Profile

A Phase I/IIa Open-label Investigation of the Safety and Effectiveness of DIABECELL [Immunoprotected (Alginate-Encapsulated) Porcine Islets for Xenotransplantation] in Patients With Type I Diabetes Mellitus

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Diabetes-cell-therapy-Diatranz-Otsuka-Limited (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Diatranz Otsuka Limited; Living Cell Technologies
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top